{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:26:18Z","timestamp":1791300378261,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jaut.2017.06.010","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T02:02:32Z","timestamp":1498788152000},"page":"58-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"special_numbering":"C","title":["Inflammation and myeloproliferative neoplasms"],"prefix":"10.1016","volume":"85","author":[{"given":"Federico","family":"Lussana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2017.06.010_bib1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2017.06.010_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2017.06.010_bib3","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2017.06.010_bib4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A\u00a0unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2017.06.010_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2017.06.010_bib6","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.jaut.2017.06.010_bib7","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2017.06.010_bib8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2017.06.010_bib9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jaut.2017.06.010_bib10","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2017.06.010_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","article-title":"Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression","volume":"118","author":"Klampfl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2017.06.010_bib12","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","article-title":"V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules","volume":"35","author":"Falanga","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.jaut.2017.06.010_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0033-1343890","article-title":"JAK2 mutation-related disease and thrombosis","volume":"39","author":"Vannucchi","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.jaut.2017.06.010_bib14","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2017.06.010_bib15","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"262","author":"Carobbio","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.jaut.2017.06.010_bib16","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2017.06.010_bib17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jaut.2017.06.010_bib18","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2017.06.010_bib19","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2011-12-401455","article-title":"Risk of second cancers in chronic myeloproliferative neoplasms","volume":"119","author":"Susini","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2017.06.010_bib20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2017.06.010_bib21","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A\u00a0role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jaut.2017.06.010_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1586\/17474086.2013.876356","article-title":"Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms","volume":"7","author":"Hasselbalch","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.jaut.2017.06.010_bib23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2017.06.010_bib24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3324\/haematol.2013.094284","volume":"99","author":"Lussana","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jaut.2017.06.010_bib25","first-page":"879","article-title":"Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation","volume":"20","author":"Thiele","year":"2005","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.jaut.2017.06.010_bib26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jaut.2017.06.010_bib27","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2017.06.010_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CJI.0b013e3181d32e74","article-title":"Cancer and inflammation: promise for biologic therapy","volume":"33","author":"Demaria","year":"2010","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.jaut.2017.06.010_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/07853890903405753","article-title":"Molecular pathways and targets in cancer-related inflammation","volume":"42","author":"Mantovani","year":"2010","journal-title":"Ann. Med."},{"key":"10.1016\/j.jaut.2017.06.010_bib30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet?","volume":"339","author":"Coussens","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jaut.2017.06.010_bib31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2017.06.010_bib32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/10428190902780677","article-title":"Autoimmunity and hematologic malignancies: associations and mechanisms","volume":"50","author":"Martin","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jaut.2017.06.010_bib33","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.leukres.2013.04.007","article-title":"Myelodysplastic syndromes and autoimmune diseases\u2013case series and review of literature","volume":"37","author":"Al Ustwani","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jaut.2017.06.010_bib34","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.jaut.2017.06.010_bib35","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jaut.2017.06.010_bib36","doi-asserted-by":"crossref","first-page":"606819","DOI":"10.1155\/2015\/606819","article-title":"Inflammation as a driver of clonal evolution in myeloproliferative neoplasm","volume":"2015","author":"Fleischman","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jaut.2017.06.010_bib37","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2017.06.010_bib38","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1096\/fj.11-193078","article-title":"Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms","volume":"26","author":"Hoermann","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.jaut.2017.06.010_bib39","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/onc.2010.479","article-title":"Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F","volume":"30","author":"Boissinot","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.jaut.2017.06.010_bib40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jaut.2017.06.010_bib41","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2017.06.010_bib42","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.jaut.2017.06.010_bib43","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.jaut.2017.06.010_bib44","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jaut.2017.06.010_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases","volume":"130","author":"Panteli","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2017.06.010_bib46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2353\/ajpath.2008.071030","article-title":"Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines","volume":"172","author":"Bock","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jaut.2017.06.010_bib47","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2014-12-618595","article-title":"Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells","volume":"126","author":"Lu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2017.06.010_bib48","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","article-title":"Pathogenesis of myelofibrosis with myeloid metaplasia","volume":"23","author":"Tefferi","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.jaut.2017.06.010_bib49","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2012-06-439661","article-title":"Characterization of the TGF-beta1 signaling abnormalities in the Gata1low mouse model of myelofibrosis","volume":"121","author":"Zingariello","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2017.06.010_bib50","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1038\/bcj.2017.6","article-title":"The role of the extracellular matrix in primary myelofibrosis","volume":"7","author":"Leiva","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jaut.2017.06.010_bib51","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jaut.2017.06.010_bib52","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1001\/archinte.165.21.2479","article-title":"Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study","volume":"165","author":"Ballantyne","year":"2005","journal-title":"Arch. Intern Med."},{"key":"10.1016\/j.jaut.2017.06.010_bib53","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2017.06.010_bib54","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Kaptoge","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2017.06.010_bib55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/ije\/dyn217","article-title":"Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts","volume":"38","author":"Shah","year":"2009","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.jaut.2017.06.010_bib56","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jaut.2017.06.010_bib57","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/leu.2013.207","article-title":"Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jaut.2017.06.010_bib58","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-017-0425-z","article-title":"Driver mutations (JAK2V617F, MPLW515L\/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera","volume":"10","author":"Lussana","year":"2017","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.jaut.2017.06.010_bib59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.leukres.2017.06.004","article-title":"Primary myelofibrosis: older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease","volume":"60","author":"Barosi","year":"2017","journal-title":"Leukemia Res."},{"key":"10.1016\/j.jaut.2017.06.010_bib60","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1161\/01.CIR.0000148982.95775.BF","article-title":"CDC\/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the population science discussion group","volume":"110","author":"Fortmann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jaut.2017.06.010_bib61","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2017.06.010_bib62","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ajh.22166","article-title":"Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm","volume":"86","author":"Rumi","year":"2011","journal-title":"Am. J. Hematol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841117304304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841117304304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:16:29Z","timestamp":1760256989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841117304304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":62,"alternative-id":["S0896841117304304"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2017.06.010","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation and myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2017.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}